Go to the relevant department to request it.
The biopharmaceutical industry is regarded as a sunrise industry with rapid development momentum. With the rapid and steady growth of new product R&D expenditures, the production and sales of new products by large and medium-sized enterprises in my country's biopharmaceutical industry have shown a rapid growth trend. The following is a summary of biomedical industry data. Biomedicine is a "long-cycle, high-investment, high-risk, high-return" industry, and it is also an industry that is "highly regulated by the government." It is in great need of capital to promote development, but it cannot be matured by capital. Only by investing in "slow companies" with core technologies can we stand out in the complex biomedical field. Investing in "slow" is an investment in technology and an investment in the future. Therefore, some biotech companies whose R&D drugs have reached the clinical stage and are relatively mature will be more popular.